Skip to content

NIPT (non-invasive prenatal testing) explained

A simple blood draw that screens for the most common chromosomal conditions — and tells you biological sex earlier than any other method.

Written and reviewed by the babybumpkit editorial team.

What NIPT is

NIPT (non-invasive prenatal testing, also called cell-free DNA screening or cfDNA) is a blood test ordered during pregnancy that looks at small fragments of placental DNA circulating in the mother's blood. Because placental DNA is genetically identical to the baby's, analyzing it lets the lab estimate the risk of certain chromosomal conditions.

NIPT is a screening test, not a diagnostic test. That distinction matters: it tells you the probability that something is present, not a yes-or-no answer. A positive screening result needs a diagnostic follow-up (typically CVS or amniocentesis) to confirm.

NIPT became widely available around 2011 and is now one of the most common prenatal tests in countries that fund or insure it. In the US, ACOG and SMFM recommend offering it to all pregnant patients regardless of age or risk factors.

When you can get NIPT

NIPT is reliable from 9–10 weeks of gestation onwards. Earlier than that, there isn't enough fetal DNA in the mother's bloodstream to analyze confidently — the test would have a higher rate of inconclusive results.

Most providers order NIPT between 10 and 13 weeks, often as part of the first-trimester screening visit. It can be done later in pregnancy too — there's no upper limit — but the early-pregnancy timing means you get information when treatment options (if needed) are widest.

The blood draw takes a few minutes. Results typically come back in 7–14 days.

What NIPT screens for

Standard NIPT panels screen for the three most common autosomal trisomies (an extra copy of a chromosome): trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). These are the conditions where screening has the strongest evidence base.

Most labs also offer sex-chromosome analysis: presence of X and Y chromosomes (which determines biological sex) and detection of sex-chromosome variations like Turner syndrome (45,X) and Klinefelter syndrome (47,XXY). The sex-determination part is what makes NIPT popular with parents who want to know biological sex early — it's accurate from 9–10 weeks onward.

Expanded NIPT panels (sometimes called 'NIPT plus') screen for additional micro-deletion syndromes like DiGeorge or Prader-Willi. The detection rates for these conditions are lower than for the main trisomies, and the false-positive rate is higher, so expanded NIPT is offered selectively rather than universally.

What NIPT doesn't screen for: most single-gene disorders, structural abnormalities (those need ultrasound), neural tube defects (that's what alpha-fetoprotein measures), or rare chromosomal variations beyond the listed panel.

How accurate is NIPT?

For trisomy 21 (Down syndrome) in the average-risk population, NIPT has a detection rate around 99% and a false-positive rate around 0.1%. That's substantially better than older screening methods like the first-trimester combined screening or the quad screen.

Accuracy for trisomies 18 and 13 is slightly lower (~97% detection, marginally higher false-positive rate). Sex-chromosome analysis is also very accurate but with somewhat higher false positive rates.

A 'positive' NIPT result actually means 'screen-positive' — the test suggests higher-than-baseline risk, not that the condition is present. The positive predictive value (PPV) — the probability that a positive screen is a true positive — depends heavily on the mother's age and the specific condition. For Down syndrome in a 25-year-old, PPV is around 50%; for the same screen-positive at 40, PPV is closer to 90%. This is why providers always recommend confirmatory diagnostic testing (CVS or amnio) after a positive NIPT.

Cost and insurance

In the US, NIPT typically runs $300–$2,000 list price, often substantially less with insurance. Many insurers cover NIPT for everyone now that professional societies recommend universal offering; others still restrict coverage to 'high-risk' pregnancies (advanced maternal age, family history, abnormal earlier screening). Check with your insurer before testing.

In countries with single-payer healthcare (UK, Canada, Australia, most of Europe), NIPT is often available either free or at low cost for higher-risk pregnancies, with self-pay options for everyone else. The exact rules vary by country and region.

What to do with a positive result

A positive NIPT result is a signal to schedule diagnostic testing — chorionic villus sampling (CVS, available 10–13 weeks) or amniocentesis (available from ~15 weeks). These tests look directly at fetal cells and give a definitive answer.

Many people feel pressure to make rapid decisions after a positive screen. Don't. Take time to talk with your provider and a genetic counselor; ask for a clear explanation of the positive predictive value for your specific situation; and remember that screen-positive often does not mean the condition is present.

Genetic counselors are specifically trained to walk through these results. Most providers can refer you to one; many insurance plans cover the consultation. Their job is to explain options, not to push a decision either way.

Frequently asked questions

No, but NIPT-based paternity testing exists as a separate service from the same blood-draw technology. Standard NIPT screens for chromosomal conditions and biological sex. Non-invasive prenatal paternity tests (NIPP) use related cfDNA technology to compare fetal DNA against a putative father's DNA. They're a separate test, separately priced, ordered for a different reason.

Sources and medical references

Related calculators